[Primary dysmenorrhea. Severe primary dysmenorrhea treated with the selective beta-adrenergic stimulating agent ritodrine chloride]. The use of isoxsuprine in essential dysmenorrhea. A controlled clinical study. Isoxsuprine in primary dysmenorrhoea. Its effectiveness in premenstrual tension. Terbutaline inhalation for alleviation of severe pain in essential dysmenorrhea. Beta-receptor stimulation in essential dysmenorrhea.
nan The "uterus-specific" beta-adrenoceptor stimulator isoxsuprine was used for the treatment of primary dysmenorrhea in a double-blind controlled clinical study. No significant beneficial effect of the drug was evident. The drug combination including isoxsuprine 10 mg, acetaminophen 250 mg and caffeine 30 mg was administered to 80 patients divided into two groups, 40 with premenstrual tension and 40 with clinically diagnosed primary dysmenorrhoea. The study was carried out by the double-blind method and the patients were distributed at random. The results obtained show an excellent or very good response in 95% of cases of premenstrual tension and in 92.5% of cases of dysmenorrhoea. When the overall effectiveness of the compound in both conditions is considered, we find it to be 93.75%. A general discussion of the findings is presented in relation to age, civil status, time of appearance of dysmenorrhoea, nature of pain, accompanying symptoms, previous treatment, other non-drug therapies, results obtained, time within which symptoms were alleviated, total dose of the drug and side-effects. It is concluded that the orally-administered therapeutic combination is effective in both dysmenorrhoea and premenstrual tension. In a double-blind cross-over study the effect of terbutaline spray (Bricanyl aerosol) inhalations was tested in 14 women with severe dysmenorrhea. A significant relief was noted in association with an increased menstrual blood loss. The side effects were few. nan
The evidence presented in this review was based on a few relatively small-sized studies that were categorised to have unclear to high risk of bias, which does not allow confident decision-making at present about the use of beta2-adrenoceptor agonists for dysmenorrhoea. The benefits as reported in one study should be balanced against the wide array of unacceptable side effects documented with this class of medication. We have emphasised the lack of precision and limitations in the reported data where appropriate.